Table 16.8 Melanoma of the Skin (Invasive)

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival	. (Percent)								
Year of Diagnosis:									
1960-1963 ^a	-	-	-	60	51	68	_	-	_
1970-1973 ^a	-	_	=	68	62	75	-	_	_
1975–1977 ^b	81.9	77.5	86.3	82.0	77.8	86.2	56.7 ^g	-	-
1978-1980 ^b	82.7	77.7	87.7	82.8	77.8	87.8	59.8 ^h	-	-
1981-1983 ^b	82.8	78.4	87.3	82.7	78.4	87.2	61.9 ^g	_	-
1984-1986 ^b	86.6	82.5	91.0	86.4	82.2	90.9	71.2 ^h	_	-
1987-1989 ^b	88.0	84.8	91.5	87.9	84.8	91.3	78.6 ^g	_	89.5 ^g
1990-1992 ^b	89.2	86.9	91.7	89.2	87.0	91.7	59.6 ^g	_	_
1993-1995 ^b	89.7	87.2	92.6	89.5	87.0	92.6	69.5 ^g	66.6 ^g	_
1996-1998 ^b	90.9	89.5	92.6	90.8	89.2	92.7	73.9 ^g	68.0 ^h	78.6 ^g
1999-2001 ^b	92.1	90.1	94.6	92.2	90.2	94.6	73.2 ^g	69.6 ^g	76.1 ^g
2002-2005 ^b	93.1	91.2	95.4	93.2	91.2	95.6	74.1 ^g	68.0 ^h	70.1°
2006-2012 ^b	93.2 ^f	91.5 ^f	95.2 ^f	93.2 ^f	91.6 ^f	95.1 ^f	69.1	58.9 ^g	76.2 ^g
5-Year Period Survival (Percent)cd								
2012	91.6	89.6	94.2	91.2	89.1	94.0	65.9	59.4	69.8
Stage Distribution (%) 2	2006-2012 ^{ce}								
All Stages		- 4 - 600	40 500		= 4 000	00 540	4.70	4.05	0.75
Number of cases	97,325	54,623	42,702	90,839	51,290	39,549	473	197	276
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	84	82	86	84	82	86	54	45	61
Regional	9	10	7	9	10	8	26	30	22
Distant	4	5	3	4	5	3	15	18	12
Unstaged	3	3	3	3	3	3	6	8	4
5-Year Relative Survival	. (Percent), 2	2006-2012°							
Age at Diagnosis:	0.4 4	01 0	96.7	94.2	90.7	96.6	82.0	69.3 ^g	88.2
Ages <45	94.4	91.0							
Ages 45-54	92.6	90.1	95.3	92.3	89.6	95.2	66.1 ^g	63.3 ^g	68.2 ^g
Ages 55-64	91.3	89.6	94.0	90.9	89.2	93.7	67.7 ^g	58.4 ^g	79.1 ^g
Ages 65-74	91.9	90.7	94.2	91.7	90.4	94.1	62.3 ^g	54.8 ^g	67.6 ^g
Ages 75+	85.9	85.7	86.3	85.4	85.2	85.8	56.1 ^g	51.7 ^h	56.0 ^g
Ages <65	92.7	90.1	95.5	92.4	89.7	95.4	72.3	62.9 ^g	79.3
Ages 65+	89.2	88.5	90.3	88.8	88.1	90.0	59.7 ^g	54.1 ^g	61.2 ^g
Stage ^e :									
All Stages	91.5	89.5	94.0	91.1	89.1	93.8	67.3	59.9	71.7
Localized	98.4	97.8	99.0	98.2	97.5	98.9	90.0	96.1	86.1
Regional	62.4	59.6	67.0	62.6	60.1	67.1	46.7 ^g	34.1 ^g	57.6 ^g
Distant	17.9	16.1	21.7	17.7	16.1	21.1	21.6 ^g	15.5 ^g	30.0 ^g
Unstaged	81.2	78.9	84.1	80.2	77.5	83.5	55.1 ^h	-	-

Based on End Results data from a series of hospital registries and one population-based registry.

SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Based on follow-up of patients into 2013.

SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Based on follow-up of patients into 2013.

Period survival provides a 2012 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2010-2012: 0-1 year survival),

^{(2009-2011: 1-2} year survival), (2008-2010: 2-3 year survival), (2007-2009: 3-4 year survival), (2006-2008: 4-5 years survival).

Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding. The difference between 1975-1977 and 2006-2012 is statistically significant (p<.05).

The standard error is between 5 and 10 percentage points.

The standard error is greater than 10 percentage points.

Statistic could not be calculated due to fewer than 25 cases during the time period.